Stock SRPT SAREPTA THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Sarepta Therapeutics, Inc.

Equities

SRPT

US8036071004

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 21:00:00 26/04/2024 BST 		5-day change 1st Jan Change
128.8 USD +1.08% Intraday chart for Sarepta Therapeutics, Inc. +11.37% +33.54%
03-21 FDA greenlights Italfarmaco's drug for rare muscular dystrophy RE
03-12 Transcript : Sarepta Therapeutics, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-12-2024 03:05 PM

Business Summary

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on helping patients through the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. It has developed multiple approved products for the treatment of Duchenne muscular dystrophy (Duchenne) and is developing potential therapeutic candidates for a range of diseases and disorders, including Duchenne, Limb-girdle muscular dystrophies (LGMDs) and other neuromuscular and central nervous system (CNS) related disorders. It has developed and commercialized four approved products for the treatment of Duchenne: EXONDYS 51 (eteplirsen), Injection (EXONDYS 51), VYONDYS 53 (golodirsen) Injection (VYONDYS 53), AMONDYS 45 (casimersen) Injection (AMONDYS 45), and ELEVIDYS. Its pipeline includes approximately 40 programs at various stages of discovery, pre-clinical and clinical development.

Number of employees: 1,314

Sales per Business

USD in Million2022Weight2023Weight Delta
RNA-targeted Therapeutics, Gene Therapy and Other Genetic Therapeutic Modalities
100.0 %
933 100.0 % 1,243 100.0 % +33.26%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
100.0 %
933 100.0 % 1,243 100.0 % +33.26%

Managers

Managers TitleAgeSince
Douglas Ingram CEO
 Chief Executive Officer 61 25/06/17
Ian Estepan DFI
 Director of Finance/CFO 48 31/12/14
Bilal Arif CTO
 Chief Tech/Sci/R&D Officer - -
Louise Rodino-Klapac CTO
 Chief Tech/Sci/R&D Officer 48 31/05/18
Will Tilton HRO
 Human Resources Officer - -
Alison Nasisi HRO
 Human Resources Officer - -
Dallan Murray PRN
 Corporate Officer/Principal - 31/12/12
Diane Berry PRN
 Corporate Officer/Principal - 30/11/11
Ryan Brown LAW
 General Counsel 46 31/12/17
Joseph Bratica AUD
 Comptroller/Controller/Auditor 60 28/02/17

Members of the board

Members of the board TitleAgeSince
Douglas Ingram CEO
 Chief Executive Officer 61 25/06/17
M. Wilsey CHM
 Chairman 71 30/03/09
Richard Barry BRD
 Director/Board Member 65 01/06/15
Hans Lennart Rudolf Wigzell BRD
 Director/Board Member 86 31/05/10
Stephen Mayo BRD
 Director/Board Member 62 15/11/21
Claude Nicaise BRD
 Director/Board Member 71 01/06/15
Michael Chambers BRD
 Director/Board Member - 01/06/22
Kathryn Boor BRD
 Director/Board Member 65 01/06/22

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 94,505,608 89,898,718 ( 95.13 %) 0 95.13 %

Shareholders

NameEquities%Valuation
Vanguard Fiduciary Trust Co.
9.393 %
8,816,124 9.393 % 1 141 M $
BlackRock Advisors LLC
5.935 %
5,569,971 5.935 % 721 M $
Janus Henderson Investors US LLC
5.696 %
5,345,785 5.696 % 692 M $
Capital Research & Management Co. (International Investors)
5.052 %
4,741,485 5.052 % 614 M $
Avoro Capital Advisor LLC
4.629 %
4,344,444 4.629 % 562 M $
Wellington Management Co. LLP
4.398 %
4,127,610 4.398 % 534 M $
Richard Barry
3.390 %
3,181,688 3.390 % 412 M $
STATE STREET CORPORATION
2.556 %
2,399,078 2.556 % 311 M $
BNY Mellon Investment Adviser, Inc.
2.202 %
2,067,037 2.202 % 268 M $
T. Rowe Price Investment Management, Inc.
2.045 %
1,919,742 2.045 % 249 M $

Company contact information

Sarepta Therapeutics, Inc.

215 First Street Suite 415

02142, Cambridge

+617 274 4000

http://www.sareptatherapeutics.com
address Sarepta Therapeutics, Inc.(SRPT)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Bio Therapeutic Drugs

Ratings for Sarepta Therapeutics, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
22
Last Close Price
128.8 USD
Average target price
164.5 USD
Spread / Average Target
+27.78%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+33.54% 12.17B
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-2.31% 103B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+0.56% 95.28B
ARGENX SE Stock argenx SE
+1.69% 22.15B
BIONTECH SE Stock BioNTech SE
-17.37% 21.02B
GENMAB A/S Stock Genmab A/S
-9.30% 18.15B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.01% 16.73B
BEIGENE, LTD. Stock BeiGene, Ltd.
-14.85% 16.05B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+3.21% 13.68B
LEGEND BIOTECH CORPORATION Stock Legend Biotech Corporation
-24.71% 8.24B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. SRPT Stock
  4. Company Sarepta Therapeutics, Inc.